Bill Anderson/LinkedIn
Nov 26, 2025, 11:37
Bill Anderson on Secondary Stroke Prevention: This Week, We’ve Reached a Significant Milestone
Bill Anderson, CEO at Bayer, shared on LinkedIn:
”Those numbers tell the story: stroke is devastating.
For patients. For families.
And after surviving, the risk of another stroke is even higher.
This week, we’ve reached a significant milestone with positive topline results from our international Phase III study in secondary stroke prevention.
Our teams worked hard to get here.
Thank you, Team Bayer, for pushing to help people who’ve already been through so much.
We’re making progress—and there’s more to do.”
Stay updated with Hemostasis Today.
-
Apr 15, 2026, 09:10Shall I Bleed Less with Age? Just 2 Weeks Until the Webinar – EHC
-
Apr 15, 2026, 08:51Moustafa Abdou: Sutimlimab is Transforming Outcomes in Cold Agglutinin Disease
-
Apr 15, 2026, 04:52Ulrich Pecks: Personalized Approaches to VTE Prevention in Pregnant Women with Inherited Thrombophilia
-
Apr 15, 2026, 04:06Brenda Pleasant: Insights from the HFA Symposium on Hemophilia Care
-
Apr 15, 2026, 03:43Lexy Halloran: Addressing Diagnostic Inequities in Women with Chronic Conditions
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS